



# Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis

Corneliu Bolbocean<sup>1</sup> · Sylvia van der Pal<sup>2</sup> · Stef van Buuren<sup>2</sup> · Peter J. Anderson<sup>3,4</sup> · Peter Bartmann<sup>5</sup> · Nicole Baumann<sup>3,6,7</sup> · Jeanie L. Y. Cheong<sup>8</sup> · Brian A. Darlow<sup>9</sup> · Lex W. Doyle<sup>8,10</sup> · Kari Anne I. Evensen<sup>11,12</sup> · John Horwood<sup>13</sup> · Marit S. Indredavik<sup>14</sup> · Samantha Johnson<sup>6</sup> · Neil Marlow<sup>15</sup> · Marina Mendonça<sup>8</sup> · Yanyan Ni<sup>8,15</sup> · Dieter Wolke<sup>16</sup> · Lianne Woodward<sup>17</sup> · Erik Verrips<sup>2</sup> · Stavros Petrou<sup>1</sup>

Accepted: 26 September 2022 / Published online: 26 October 2022  
© The Author(s) 2022

## Abstract

**Background and Objective** Assessment of health-related quality of life for individuals born very preterm and/or low birth-weight (VP/VLBW) offers valuable complementary information alongside biomedical assessments. However, the impact of VP/VLBW status on health-related quality of life in adulthood is inconclusive. The objective of this study was to examine associations between VP/VLBW status and preference-based health-related quality-of-life outcomes in early adulthood.

**Methods** Individual participant data were obtained from five prospective cohorts of individuals born VP/VLBW and controls contributing to the ‘Research on European Children and Adults Born Preterm’ Consortium. The combined dataset included over 2100 adult VP/VLBW survivors with an age range of 18–29 years. The main exposure was defined as birth before 32 weeks’ gestation (VP) and/or birth weight below 1500 g (VLBW). Outcome measures included multi-attribute utility scores generated by the Health Utilities Index Mark 3 and the Short Form 6D. Data were analysed using generalised linear mixed models in a one-step approach using fixed-effects and random-effects models.

**Results** VP/VLBW status was associated with a significant difference in the Health Utilities Index Mark 3 multi-attribute utility score of  $-0.06$  (95% confidence interval  $-0.08, -0.04$ ) in comparison to birth at term or at normal birthweight; this was not replicated for the Short Form 6D. Impacted functional domains included vision, ambulation, dexterity and cognition. VP/VLBW status was not associated with poorer emotional or social functioning, or increased pain.

**Conclusions** VP/VLBW status is associated with lower overall health-related quality of life in early adulthood, particularly in terms of physical and cognitive functioning. Further studies that estimate the effects of VP/VLBW status on health-related quality-of-life outcomes in mid and late adulthood are needed.

## 1 Introduction

Very preterm (VP; <32 weeks gestation) birth or very low birthweight (VLBW; <1500 g) is associated with increased mortality [1–3], adverse neurodevelopmental outcomes [4–6] and a greater socioeconomic disadvantage extending into early to mid-adulthood [7–10]. Prematurity is a growing public health concern as increasing preterm birth rates coupled with improvements in survival rates place increased pressures on healthcare budgets worldwide [11–13]. Furthermore, the long-term adverse psychological

### Key Points for decision makers

Very preterm birth or very low birth weight status was associated with a significant difference in the Health Utilities Index Mark 3 multi-attribute utility score of  $-0.06$  (95% confidence interval  $-0.08, -0.04$ ) in comparison to birth at term or at normal birthweight; this was not replicated for the Short Form 6D.

Impacted functional domains included vision, ambulation, dexterity and cognition.

Very preterm birth or very low birth weight status is associated with lower overall health-related quality of life in early adulthood, particularly in terms of physical and cognitive functioning.

✉ Corneliu Bolbocean  
Corneliu.Bolbocean@phc.ox.ac.uk

Extended author information available on the last page of the article

and economic consequences of preterm birth on families, such as the increased risk of anxiety and depression and increased out-of-pocket expenses, are well documented [14–17]. Policies and interventions to improve outcomes in such populations are needed and should include the consideration of health-related quality of life (HRQoL). Generic HRQoL measures are holistic constructs [18, 19] that are highly correlated with widely used health metrics including morbidity, mortality and healthcare costs, and have well-documented positive measurement properties for assessing health status particularly in the general population [20–22]. In particular, HRQoL measures that are accompanied by preference-based value sets generate utility scores that represent preferences for health states on a 0–1 cardinal scale where 0 represents being dead and 1 represents full health. Health utilities can inform health economic and policy evaluations [23–25] and are also helpful for understanding an individual's current health status with respect to the particular attributes or dimensions considered within each instrument. Furthermore, HRQoL measures that are accompanied by preference-based value sets have become increasingly important in understanding daily impacts on individual functioning when included in clinical studies [26–29].

While prospective cohort studies have generally highlighted the adverse effects of VP birth on longer term health and developmental outcomes, there is limited and conflicting evidence about its impact on HRQoL outcomes in adulthood [7, 30]. Some studies suggest that it is associated with lower utility scores that persist into early adulthood [30–34], while others find no conclusive relationship [7, 8, 35–38]. Furthermore, it remains unclear whether, and to what degree, perinatal and early life factors are associated with HRQoL in adulthood.

Research into the long-term outcomes of individuals born VP/VLBW is subject to methodological challenges primarily owing to sample attrition in cohort studies over time [39], which often disproportionately results in the loss of participants from socioeconomically disadvantaged families [40–42], and in participants with more impaired outcomes [43]. In some cohort studies, this has led to relatively small samples and weak external validity of the study results [7]. To overcome the limitations associated with analyses restricted to single cohorts or studies with weak external validity, the use of an individual patient data analysis consolidated over several cohorts has advantages and, with harmonisation of data, allows a detailed examination of associations between VP/VLBW status and a range of outcomes. Previous research has advocated new studies that build upon current knowledge and exploit gains from larger samples that both strengthen statistical power and allow multivariable and subgroup analyses to be performed when data across multiple cohort studies are combined [7, 30]. Such research

should provide much needed data to inform policy efforts around VP/VLBW status and its long-term consequences.

This study had the following aims: (a) to estimate the association between VP/VLBW status and preference-based HRQoL outcomes in early adulthood by pooling harmonised data from five prospective longitudinal birth cohort studies and (b) to identify the specific aspects of HRQoL in early adulthood that are associated with VP/VLBW status.

## 2 Methods

### 2.1 Study Cohorts

For inclusion in this analysis, prospective cohort studies were required to (1) have measured the HRQoL in adulthood (defined as age  $\geq 18$  years [44]) of individuals born VP/VLBW using preference-based measures; (2) included a comparison control group of term-born or normal birthweight individuals, and (3) contributed data to the Research on European Children and Adults Born Preterm (RECAP) Consortium ([www.recap-preterm.eu](http://www.recap-preterm.eu)), a database of cohorts of individuals born VP/VLBW. Eligible cohorts were identified by a recent systematic review of preference-based HRQoL outcomes following preterm birth or low birthweight [30]. The review identified seven cohorts that measured HRQoL in adulthood of individuals born VP/VLBW using preference-based measures, one of which (POPS) did not include a comparison control group of term-born or normal birthweight individuals [45], whilst data from the McMaster cohort [31] were not contributed to the RECAP platform. Five prospective cohort studies therefore contributed to the study: the Bavarian Longitudinal Study (BLS) [46], the Victorian Infant Collaborative Study (VICS) [47], the EPICure study [48], the New Zealand Very Low Birth Weight (NZ-VLBW) study [49] and the Norwegian University of Science and Technology (NTNU) Low Birth Weight in a Lifetime Perspective (NTNU LBW Life) study [50]. The included studies were primarily designed to investigate the associations of VP/VLBW status with health outcomes [51] and had received country-specific ethical reviews along with participants' written informed consent in adulthood. This analysis used records from the start of data collection up to the earliest assessments in adulthood (BLS at 26 years, VICS at 18 years, EPICure at 19 years, NTNU LBW Life at 19 years and NZ-VLBW at 22–23 years). In addition, we undertook a further analysis that also included repeated HRQoL assessments at 23 and 28 years for the NTNU LBW Life and NZ-VLBW cohorts, respectively.

Table 1 details the background characteristics of the samples in each cohort, including eligibility criteria, age(s) of assessment in adulthood and the composition of control groups. Additional details for each study can be found in

published research as follows: BLS [46], VICS [47], NTNU LBW Life [50], EPICure [48] and NZ-VLBW [49]. The process of harmonising data across RECAP cohorts involved the application of an identical set of definitions, scaling methods and categorisations of all variables included in the analyses. Dictionaries were developed to guide harmonisation of all variables of interest across studies.

## 2.2 Outcome Measures

Participants' perceptions of their current health status were assessed using at least one of the following self-report measures: Health Utilities Index Mark 3 (HUI3) [BLS, VICS and EPICure] and either the Short Form 12 (SF-12) or Short Form 36 (SF-36) (BLS, VICS, NZ-VLBW and NTNU LBW Life). The NZ-VLBW and NTNU LBW Life cohorts administered the SF-12/SF-36 at two different ages in adulthood. The BLS and VICS studies assessed HRQoL using both the HUI3 and SF-12 or SF-36 measures at one age only [46, 47].

The HUI3 comprises eight attributes: vision; hearing; speech; emotion; pain; ambulation; dexterity; and cognition [52–54]. Levels of function within each attribute were scored on a 5-point or 6-point scale with a range from normal/optimal function to severe impairment. Responses were mapped onto an eight-attribute health status vector and eight single attribute utility (SAU) scores were computed [52]. Responses to the HUI3 health status classification system were subsequently converted into multiplicative multi-attribute utility (MAU) scores using the Canadian algorithms [52–55]. HUI3 MAU scores range from  $-0.36$  and  $1.0$ , with  $-0.36$  representing the worst possible HUI3 health state,  $0$  representing being dead, and  $1.0$  representing full health [54, 55]. Most HUI3 attributes reflect objective aspects of the health of the individual (vision, hearing, speech, ambulation, dexterity and cognition).

The SF-36 health status assessment questionnaire was designed to describe HRQoL using 36 items and yields an eight-dimension health profile: physical functioning, physical role limitations, social functioning, bodily pain, general health, mental health, vitality and emotional role limitations. The SF-12 includes 12 of the 36 items from the SF-36 with an identical dimension structure. For each dimension, responses to the survey items are transformed into a scale from 0 to 100, where higher scores indicate better HRQoL. Responses to the SF-36/12 items were converted [56] into SF-6D MAU scores for each participant using the UK SF-6D utility algorithms [57]. The SF-6D algorithms also reduce the eight dimensions of the SF-36/12 to six by combining role limitations due to physical and emotional problems and omitting general health perceptions. The SF-6D MAU scores range between 0 and 1.0, with 0 representing being dead and 1.0 representing full health [57]. A minority of the SF-6D dimensions (physical functioning, role limitations) reflect

physical dimensions, while the remaining dimensions (pain, social functioning, mental health, emotional and vitality) reflect more socio-emotional aspects of health.

For the main analysis, we utilised HUI3 MAU scores and SF-6D MAU scores. However, additional analyses considered the following outcome variables: indicator variables that denote optimal levels of function across each health attribute or dimension, HUI3 SAU scores and SF-12 dimension scores. Appendix A of the Electronic Supplementary Material (ESM) provides additional details regarding the HUI3 and SF-6D measures as well as data on the strength of relationship between them in our study data. For both measures, differences in MAU scores equal or greater to 0.04 were considered clinically significant [58, 59].

## 2.3 Main Exposure

The main independent variable in this study was an indicator for VP or VLBW status, i.e. whether an individual was born  $<32$  weeks' gestation or  $\leq 1500$  g. Additionally, we assessed the association of VP birth only on HUI3 and SF-6D outcomes, regardless of birthweight status.

## 2.4 Covariates

Independent variables incorporated into the analyses were previously shown to be associated with the HRQoL of those born preterm or low birthweight [34, 45]: sex (male (referent)), age at assessment (measured in years), and mother's level of education harmonised according to the International Standard Classification of Education (ISCED) into low (ISCED levels 0–2), medium (ISCED levels 3–5) and high (ISCED levels 6–8) [60] [low maternal education (referent) category in all models]. We additionally accounted for cohort effects using indicator variables for each cohort.

## 2.5 Empirical Analyses

Given the structure of the data, we combined individual participant data (IPD) across cohorts as follows: the HUI3 meta-cohort included data from BLS, VICS and EPICURE; and the SF-6D meta-cohort comprised data from BLS, VICS, NZ-VLBW and NTNU LBW Life. We designed an empirical strategy to examine the association between VP/VLBW status and HRQoL outcomes in adulthood across combined cohorts using generalised mixed models in a one-step approach, and estimated via logistic and linear probability models. The one-stage IPD analysis could be implemented either using a fixed-effects or random-effects model. [61]

In our study, cohort study participants were enrolled across different geographical regions, ages and time frames, which suggests the presence of systematic differences across

Table 1 Background characteristics of cohorts

	BLS (Germany)				VICs (Australia)				EPICure (UK and Ireland)				NZ-VLBW (New Zealand)				NTNU (Norway)	
	HUI3 at 26 years		SF-6D at 26 years		HUI3 at 18 years		SF-6D at 18 years		HUI3 at 19 years		SF-6D at 22-23 years		SF-6D at 26-30 years		SF-6D at 19 years		SF-6D at 23 years	
	VP/VLBW	Controls	VP/VLBW	Controls	EP/ELBW	Controls	EP/ELBW	Controls	EP	Controls	VP/VLBW	Controls	VP/VLBW	Controls	VP/VLBW	Controls	VP/VLBW	Controls
Number completing MAUI	231	224	231	226	186	137	180	143	110	62	230	68	243	100	52	73	33	35
Age at assessment, mean (SD)	26.3 (0.7)	26.3 (0.7)	26.3 (0.7)	26.3 (0.7)	17.9 (0.8)	18.0 (0.9)	18.0 (0.8)	18.1 (0.9)	19.3 (0.6)	19.2 (0.5)	23.4 (0.5)	23.7 (0.6)	28.5 (1.1)	28.3 (0.9)	19.7 (0.8)	19.7 (0.6)	22.5 (0.0)	22.7 (0.6)
GA at birth, mean (SD)	30.6 (2.2)	39.7 (1.3)	30.6 (2.2)	39.7 (1.2)	26.7 (2.1)	39.2 (1.4)	26.7 (2.1)	39.2 (1.4)	24.5 (0.7)	N/A	29.19 (2.5)	N/A	29.20 (2.5)	N/A	29.12 (2.4)	39.74 (1.2)	28.82 (2.7)	39.46 (1.1)
Birth weight, mean (SD)	1330.1 (319.5)	3360.0 (447.9)	1329.7 (319.4)	3362.3 (446.8)	886.7 (155.3)	3419.1 (468.0)	885.7 (155.1)	3421.5 (462.5)	745.9 (119.4)	N/A	1145.4 (238.4)	N/A	1134.5 (235.8)	N/A	1243.4 (202.8)	3718.9 (478.0)	1194.9 (254.7)	3610.6 (365.0)
Male sex, N (%)	125 (54.1)	105 (46.9)	124 (53.7)	105 (46.5)	84 (45.2)	60 (43.8)	82 (45.6)	60 (42.0)	51 (46.4)	23 (37.1)	104 (45.2)	33 (48.5)	103 (42.4)	37 (37.0)	22 (42.3)	30 (41.1)	13 (39.4)	15 (42.9)
Study name	Bavarian Longitudinal Study				Victorian Infant Collaborative Study				EPICure				New Zealand Very Low Birth Weight				Norwegian University of Science and Technology	
Birth year	1985-6				1991-2				1995				1986				1986-8	
Eligibility criteria	VP/VLBW (GA <32 wk or BW <1500 g)				EP/ELBW (GA <28 wk or BW <1000 g)				EP (GA <26 wk)				VLBW <1500 g				VLBW <1500g	
Controls	Recruited in the same obstetric hospitals				Normal birth weight, contemporaneously recruited				Recruited at school age				Age matched				Born to mothers of a 10% random sample, contemporaneously recruited	

BW body weight, GA gestational age, ELBW extremely low birth weight (<1000 g), EP extremely preterm (<26 wk GA for EPICure and <28 wk GA for VICs), HUI3 Health Utilities Index Mark 3, MAUI multi-attribute utility instrument, N/A not applicable/measurement not administered, SD standard deviation, SF-6D Short Form 6D, VLBW very low birth weight (<1500 g), VP very preterm (<32 wk GA), wk weeks

Additional details for each study can be found in published research as follows: BLS [46], VICs [47], NTNU LBW Life [50], EPICure [48] and NZ-VLBW [49]

cohorts (Table 1). Study participants also shared common characteristics that were fixed across geographic and socioeconomic dimensions caused by study-specific or country-specific factors. While this motivated the use of fixed-effects models, we performed formal tests to identify whether the IPD meta-analysis should be performed using fixed-effects or random-effects models. Details are provided in Appendix B of the ESM.

For the main analysis, we used a fixed-effects one-stage IPD analysis, and the earliest available HRQoL assessments during adulthood for each cohort as described in Table 1, for each of the following outcomes: indicator variables that denoted optimal levels of function across each attribute or dimension for each outcome measure, HUI3 SAU and MAU scores, SF-12 dimension scores and SF-6D MAU scores. To further investigate the robustness of findings, we implemented the following robustness checks: (a) we utilised linear mixed models in a one-step approach, which modeled cohort effects as random effects and (b) we included all HRQoL assessments available for all participants in the longitudinal analyses, applying the fixed-effects and random-effects models. Analyses were performed using STATA version 16 and  $p$ -values of 0.05 or less were considered statistically significant.

### 3 Results

#### 3.1 Baseline Characteristics of Prospective Cohort Studies

Table 1 reports baseline sample characteristics of each cohort. Pooled data from the five cohorts totaled 873 VP/VLBW individuals and 694 controls for the HUI3 meta-cohort and 909 VP/VLBW individuals and 680 controls for the SF-6D meta-cohort. Years of birth ranged from 1985 to 1995, and mean age at assessment varied from 18 to 28 years. Table 2 describes the characteristics of VP/VLBW individuals and controls with non-missing HUI3 and SF-6D MAU scores. Within the HUI3 meta-cohort, cases were slightly younger at assessment compared with controls, and had lower levels of maternal educational attainment compared with controls. In contrast, these differences were not apparent in the SF-6D meta-cohort but more cases in this cohort tended to have non-Caucasian ethnicity.

#### 3.2 IPD Meta-Analysis

Table 3 shows the results from logistic regression models for optimal levels of function and linear probability models for SAU scores within the HUI3 meta-cohort. Analogous estimates for the SF-6D meta-cohort are presented in Table 4. Results from the one-stage meta-analysis presented

in Table 3 demonstrate that VP/VLBW status was associated with sub-optimal levels of function and lower SAU scores for the following HUI3 attributes: vision, speech, emotion, ambulation, dexterity and cognition. Within the SF-12 cohort, VP/VLBW status was associated with sub-optimal physical functioning and social functioning, which contrasts with higher odds of optimal levels of function for the following SF-6D dimensions: role limitations, mental health and vitality.

Using a one-stage IPD meta-analysis, we considered HUI3 and SF-6D MAU scores as outcome variables (Table 5). The adjusted impact of VP/VLBW status on the HUI3 MAU score was  $-0.06$  (95% confidence interval [CI]  $-0.08, -0.04$ ) with no significant impact on SF-6D MAU scores. Results from analyses that restricted cases to very preterm status alone were similar for the HUI3 MAU score,  $-0.04$  (95% CI  $-0.06, -0.01$ ), again with no association with SF-6D MAU scores.

Higher levels of maternal education (high vs low) were associated with a higher HUI3 MAU score (mean difference 0.06; 95% CI 0.03, 0.10). Female individuals had lower MAU scores than male individuals for the SF-6D (mean difference  $-0.04$ , 95% CI  $-0.05, -0.02$ ), but not for the HUI3 (mean difference  $-0.01$ , 95% CI  $-0.03, 0.01$ ). There was weak evidence that increased age at assessment was associated with higher HUI3 MAU scores (mean difference 0.01, 95% CI 0.00, 0.01), but not SF-6D MAU scores (mean difference 0.00, 95% CI  $-0.00, 0.01$ ).

#### 3.3 Robustness Checks

Appendix C of the ESM reports the results of the one-stage IPD analysis that examined the impact of VP/VLBW status on HUI3 and SF-6D outcomes and modeled treated cohort effects as random effects. In this analysis, the adjusted HUI3 MAU score difference between VP/VLBW and controls was approximately  $-0.06$  (95% CI  $-0.08, -0.03$ ) [Table C1 of the ESM], whilst VP/VLBW participants had poorer function than their controls across the following HUI3 attributes: vision, pain, ambulation, dexterity and cognition (Table C2 of the ESM). In contrast, VP/VLBW status was not associated with lower SF-6D MAU scores (Table C3 of the ESM) but was associated with lower SF-12 physical functioning and social functioning scores (Table C4 of the ESM). Furthermore, analyses that used data from all available SF-6D HRQoL assessments for all participants and described in Appendix D (Table D1, D2, D3) of the ESM were again very similar to those reported in Tables 4, 5. Overall, the results remained robust as estimates derived from the fixed-effects and random-effects models broadly agreed and painted similar patterns regarding the impact of VP/VLBW status on HRQoL in early adulthood.



**Table 2** Characteristics of VP/VLBW individuals and controls within HUI3 and SF-6D meta-cohorts

	VP/VLBW	Controls	Missing/ <i>N</i> (Pct)
<b>HUI3 meta-cohort (BLS, EPICure, VICS)</b>			
<i>N</i> (%)	527 (55.5)	423 (44.5)	0/950 (0.0)
Age at QoL assessment, mean (SD)	21.92 (4.01)	22.62 (4.01)	7/950 (0.7)
Male sex, <i>N</i> (%)	260 (49.3)	188 (44.4)	
Gestational age (weeks), mean (SD)	27.9 (3.1)	39.49 (1.3)	62/950 (6.5)
Birth weight (g), mean (SD)	1051.7 (345.40)	3382.5 (455.90)	62/950 (6.5)
Maternal age at birth (years), mean (SD)	29.1 (5.3)	29.5 (4.7)	64/950 (6.7)
<b>Maternal ethnicity, <i>N</i> (%)</b>			
Caucasian	475 (92.8)	343 (95.8)	80/950 (8.4)
<b>Maternal education level at birth or during childhood, <i>N</i> (%)</b>			
Low level (equivalent to ISCED 0–2)	129 (29.7)	108 (31.1)	169/950 (17.8)
Medium level (equivalent to ISCED 3–5)	254 (58.5)	165 (47.6)	
High level (equivalent to ISCED 6–8)	51 (11.8)	74 (21.3)	
<b>SF-6D meta-cohort (BLS, VICS, NTNU, NZ)</b>			
<i>N</i> (%)	693 (57.6)	510 (42.4)	0/1203 (0.0)
Age at QoL assessment, mean (SD)	22.69 (3.39)	22.73 (3.70)	5/1203 (0.4)
Male sex, <i>N</i> (%)	332 (47.9)	228 (44.7)	0/1203 (0.0)
Gestational age (weeks), mean (SD)	29.0 (2.7)	39.5 (1.3)	68/1203 (5.6)
Birth weight at birth (g), mean (SD)	1146.7 (302.6)	3440.3 (473.4)	68/1203 (5.6)
Maternal age at birth (years), mean (SD)	28.1 (5.4)	29.6 (4.6)	72/1203 (6.0)
<b>Maternal ethnicity, <i>N</i> (%)</b>			
Caucasian	580 (89.0)	409 (96.2)	126/1203 (10.5)
<b>Maternal education level at birth or during childhood, <i>N</i> (%)</b>			
Low level (equivalent to ISCED 0–2)	198 (33.2)	109 (31.1)	256/1203 (21.3)
Medium level (equivalent to ISCED 3–5)	275 (46.1)	156 (44.4)	
High level (equivalent to ISCED 6–8)	123 (20.6)	86 (24.5)	

Characteristics for VP/VLBW individuals and controls who had non-missing HUI3 or SF-6D Multi Attribute Utility Scores

*HUI3* Health Utilities Index Mark 3, *ISCED* International Standard Classification of Education, *Pct* percent of missing values, *QoL* quality of life, *SD* standard deviation, *SF-6D* Short Form 6D, *VP/VLBW* very pre-term/very low birth weight/very preterm

## 4 Discussion

Overall, VP/VLBW status was associated with clinically significant decrements [58, 59] in the HUI3 MAU score in adulthood after adjusting for covariates. Specifically, the adjusted impact of VP/VLBW status on the HUI3 MAU score exceeded generally accepted thresholds of minimal important differences in multi-attribute utility scores for assessing effects on preference-based HRQoL outcomes [58, 59]. In contrast, our analyses did not detect differences in SF-6D MAU scores by VP/VLBW status.

One explanation for the above observations is that the HUI3 MAU score weights motor function, sensory function and cognition, which are known to be associated with clinical outcomes in VP/VLBW individuals, more highly compared with the SF-6D MAU score [62]. Furthermore, the HUI3 and SF-6D differ in terms of their conceptual underpinnings, dimension and item structures, and valuation protocols, which might also explain differences in

outputs. However, the totality of evidence suggests that the HUI3 and SF-6D results are broadly consistent and show that VP/VLBW status is primarily associated with poorer overall physical and cognitive functioning in adulthood, but not with socio-emotional or mental health. Thus, while evidence suggested a weak relationship between VP/VLBW status and SF-6D MAU scores, across all models employed, we consistently found that VP/VLBW status was associated with lower SF-12 physical and cognitive functioning scores. Moreover, results for the HUI3 revealed specific aspects of health that were most affected by VP/VLBW status because across all models and specifications employed, we found evidence that VP/VLBW status was associated with decrements in vision, ambulation, dexterity and cognition. The results demonstrate that VP/VLBW status was associated with decrements in nearly all HUI3 SAU scores, and in SF-12 physical and social functioning scores (Tables 3 and 4). However, in general, these decrements were small and attained statistical significance primarily for differences in

**Table 3** One-stage individual participant data meta-analyses for HUI3 SAU scores and MAU scores comparing VP/VLBW with control groups

Outcome	VP/VLBW N (%)	Controls N (%)	Odds ratio SE	Lower 95% CI	Upper 95% CI	P-value
HUI3-vision optimal functioning	315 (58.4)	290 (67.1)	0.55 (0.09)	0.40	0.74	<0.001
HUI3-hearing optimal functioning	524 (96.9)	425 (98.4)	0.59 (0.30)	0.21	0.78	0.30
HUI3-speech optimal functioning	446 (83.7)	390 (90.9)	0.52 (0.12)	0.32	0.84	0.01
HUI3-emotion optimal functioning	345 (64.2)	307 (71.6)	0.70 (0.11)	0.51	0.95	0.02
HUI3-pain optimal functioning	390 (72.5)	300 (69.8)	1.02 (0.16)	0.75	1.39	0.90
HUI3-ambulation optimal functioning	513 (94.8)	428 (99.3)	0.09 (0.07)	0.02	0.41	<0.001
HUI3-dexterity optimal functioning	508 (94.2)	428 (99.3)	0.09 (0.07)	0.02	0.40	<0.001
HUI3-cognition optimal functioning	337 (62.6)	320 (74.6)	0.58 (0.09)	0.42	0.79	<0.001
Outcome	VP/VLBW Mean (95% CI)	Controls Mean (95% CI)	$\beta_{VP/VLBW}$ SE	Lower 95% CI	Upper 95% CI	P-value
HUI3-MAU score	0.84 (0.82, 0.85)	0.90 (0.88, 0.91)	-0.06	-0.08	-0.04	<0.001
HUI3-vision SAU score	0.99 (0.98, 0.99)	0.99 (0.99, 0.99)	-0.00 (0.00)	-0.00	0.00	0.55
HUI3-hearing SAU score	0.97 (0.95, 0.98)	0.98 (0.97, 1.00)	-0.00 (0.00)	-0.00	0.00	0.55
HUI3-speech SAU score	0.99 (0.98, 0.99)	0.99 (0.99, 1.00)	-0.00 (0.00)	-0.01	0.00	<0.001
HUI3-emotion SAU score	0.97 (0.97, 0.98)	0.98 (0.98, 0.98)	-0.01 (0.00)	-0.01	-0.00	0.04
HUI3-pain SAU score	0.98 (0.97, 0.98)	0.98 (0.98, 0.98)	0.00 (0.00)	-0.00	0.01	0.67
HUI3-ambulation SAU score	0.99 (0.98, 0.99)	1.00 (1.00, 1.00)	-0.01 (0.00)	-0.01	-0.00	<0.001
HUI3-dexterity SAU score	0.99 (0.99, 1.00)	1.00 (1.00, 1.00)	-0.01 (0.00)	-0.01	-0.00	<0.001
HUI3-cognition SAU score	0.96 (0.95, 0.97)	0.98 (0.97, 0.98)	-0.02 (0.00)	-0.01	-0.00	<0.001

Models adjusted for: sex, maternal education, age at assessment and cohorts as fixed effects

CI confidence interval, HUI3 Health Utilities Index Mark 3, MAU multi attribute utility, SAU single attribute utility, SE standard error, VP/VLBW very preterm/very low birthweight

Optimal level of function is defined as level 1 function for each attribute of the HUI3. Logistic regression models were utilised when dependent variables were optimal level of functioning. Generalised linear mixed models were utilised when dependent variables were HUI3 MAU or HUI3 SAU scores

physical aspects of health. The pattern of results suggest that the evidence obtained from the SF-6D corroborates and is broadly consistent with the HUI3 results.

Consistent with previous systematic reviews [7, 30], higher levels of maternal education are associated with higher utility scores, including in adulthood. In fact, the differences in HUI3 MAU scores between those with mothers with low versus high education are of a similar quantum to being born VP/VLBW versus being born at term. This

has previously been shown for differences in functional outcomes such as intelligence [63, 64]. Our models detected differences between the sexes for SF-6D MAU scores as female sex was associated with a utility loss of -0.04 (95% CI -0.05, -0.02), also previously observed in published research [7, 30].

Overall, our results are consistent with previously observed patterns reported in the disability literature, which shows that preterm birth is mostly associated with physical

**Table 4** One-stage individual participant data meta-analyses for SF-6D multi-attribute utility scores and SF-12 dimension scores comparing VP/VLBW with control groups

Outcome	VP/VLBW N (%)	Controls N (%)	Odds ratio	Lower 95% CI	Upper 95% CI	p-Value
SF-6D physical optimal functioning	622 (87.9)	477 (92.4)	0.64 (0.16)	0.40	1.03	0.07
SF-6D role limitations optimal functioning	530 (75.3)	410 (79.5)	1.05 (0.02)	1.00	1.10	<0.001
SF-6D social functioning optimal level	486 (69.6)	365 (71.4)	0.88 (0.13)	0.65	1.18	0.39
SF-6D pain optimal level	545 (77.9)	388 (75.5)	1.04 (0.17)	0.76	1.43	0.81
SF-6D mental health optimal level	324 (46.6)	199 (38.9)	1.70 (0.24)	1.28	2.24	<0.001
SF-6D vitality optimal level	83 (11.9)	32 (6.2)	1.95 (0.51)	1.16	3.27	0.01

Outcome	VP/VLBW Mean (95% CI)	Controls Mean (95% CI)	$\beta_{VP/VLBW}$ SE	Lower 95% CI	Upper 95% CI	P-value
SF-6D MAU score	0.83 (0.82, 0.84)	0.83 (0.82, 0.84)	-0.01 (0.01)	-0.03	0.00	0.14
SF-12 physical functioning score	90.86 (89.27, 92.45)	94.96 (93.62, 96.30)	-4.38 (1.40)	-7.12	-1.64	<0.001
SF-12 role limitations functioning score	89.47 (87.66, 91.27)	90.00 (87.84, 92.15)	-0.11 (1.83)	-3.69	3.47	0.95
SF-12 social functioning score	87.11 (85.37, 88.85)	90.58 (89.02, 92.13)	-3.78 (1.37)	-6.48	-1.08	0.01
SF-12 pain functioning score	91.57 (90.20, 92.94)	91.68 (90.18, 93.19)	-0.24 (1.16)	-2.52	2.04	0.84
SF-12 mental health score	72.98 (71.47, 74.49)	73.53 (72.05, 75.00)	-1.76 (1.37)	-4.46	0.94	0.20
SF-12 vitality score	62.58 (60.69, 64.46)	64.19 (62.28, 66.10)	-3.40 (1.73)	-6.79	-0.02	0.05
SF-12 general health score	68.00 (66.22, 69.78)	71.70 (69.74, 73.66)	-2.96 (1.57)	-6.05	0.13	0.06
SF-12 role emotional score	87.41 (85.38, 89.44)	88.61 (86.27, 90.96)	-3.16 (2.02)	-7.12	0.79	0.12

CI confidence interval, MAU multi attribute utility, SAU single attribute utility, SE standard error, SF-6D Short-Form 6D, SF-12 Short Form-12, VP/VLBW very preterm/very low birth weight

Models adjusted for: sex, maternal education, age at assessment and cohorts as fixed effects. Optimal level of function is defined as level 1 function for each attribute of SF-6D. Logistic regression models were utilised when dependent variables were the optimal level of functioning. Generalised linear mixed models were utilised when dependent variables were SF-6D MAU or SF-12 scores

and cognitive impairments, but to a lesser degree with mental health problems [63, 65, 66]. While the differences in HRQoL scales we observe here might seem relatively small compared with effects we see in contemporaneous studies of disability, the differences may be mitigated in terms of “quality of life” because participants are reporting how they feel, as has been shown in other studies [31]. Furthermore, given the high sample size of VP/VLBW individuals in our study, it is unlikely that future studies will identify different patterns between VP/VLBW and HRQoL beyond those we report.

#### 4.1 Strengths and Limitations

The major strength of this study is the large sample size of VP/VLBW individuals and the longitudinal research design aimed at strengthening internal and external validity. Our constituent studies ascertained HRQoL outcomes using two measures, which differ in terms of their conceptual underpinnings and definitions of health. This unique feature of our pooled dataset allowed us to disaggregate the impacts of VP/VLBW status across different components of health and demonstrate that the influences on HRQoL largely relate to areas of physical and cognitive functioning identified as



**Table 5** One-stage individual participant data meta-analyses: impact of VP/VLBW on HUI3 MAU score and SF-6D MAU score, all cohorts combined. Method: linear fixed-effects model

	HUI3 MAU score						SF-6D MAU score					
	Unadjusted		Adjusted		P-value/N	P-value/N	Unadjusted		Adjusted		P-value/N	P-value/N
	95% CI	95% CI	95% CI	95% CI	95% CI		95% CI	95% CI	95% CI			
$\beta_{VP/VLBW}$	-0.06 (0.01)	-0.08, -0.04	0.00/950	-0.06 (0.01)	-0.08, -0.04	<0.001/781	-0.01 (0.01)	-0.02, 0.01	0.28/1203	-0.01 (0.01)	-0.03, 0.00	0.14/947
Sex (female)				-0.01 (0.01)	-0.03, 0.01	0.52				-0.04 (0.01)	-0.05, -0.02	<0.001
Maternal education (medium vs low)				0.03 (0.01)	-0.02, 0.06	0.07				0.01 (0.00)	-0.01, 0.02	0.30
Maternal education (high vs low)				0.06 (0.01)	0.03, 0.10	<0.001				0.02 (0.00)	-0.00, 0.04	0.08
Age at assessment				0.01 (0.00)	0.00, 0.01	0.05				0.00 (0.00)	-0.00, 0.01	0.61
Cohort effects included	No			Yes			No			Yes		
B < 32	-0.05 (0.01)	-0.08, -0.03	0.00/888	-0.04 (0.01)	-0.06, -0.01	<0.001/682	-0.01 (0.01)	-0.02, 0.00	0.15/1135	-0.01 (0.01)	-0.03, 0.00	0.09/947
Sex (female)				-0.00 (0.01)	-0.02, 0.02	0.77				-0.04 (0.01)	-0.05, -0.02	<0.001
Maternal education (medium vs low)				0.02 (0.01)	0.01, 0.04	<0.001				0.01 (0.01)	-0.00, 0.01	0.32
Maternal education (high vs low)				0.02 (0.01)	0.01, 0.04	<0.001				0.02 (0.00)	-0.00, 0.01	0.8
Age at assessment				0.01 (0.00)	0.00, 0.01	0.01				0.00 (0.00)	-0.00, 0.01	0.79
Cohort effects included	No			Yes			No			Yes		

HUI3 MAU column results are based on the following cohorts: BLS at 26, EPICure at 19, VICS at 18. SF-6D MAU column results are based on the following cohorts: BLS at 26, VICS at 18, NZ at 22–23, NTNU at 19. Robust standard errors in round parentheses

CI confidence interval, HUI3 Health Utilities Index Mark 3, MAU multi attribute utility, SF-6D Short Form 6D, VP/VLBW very preterm/very low birth weight

common associates of preterm birth [64, 65]. Although the mental health aspects of VP/VLBW outcomes are also well known [14, 67], within the two HRQoL measures we applied we found no effect. The use of both fixed-effects and random-effects models to investigate the relationship between VP/VLBW status and HRQoL is also a strength as this confirmed the robustness of our results.

The contributing cohorts used reliable and valid methods to recruit participants and maintained substantial participation rates throughout follow-up amongst study cases and controls. Finally, the use of adult self-report HRQoL data avoids biases associated with proxy parental reporting. From the childhood literature, child-proxy agreement around descriptions of children's HRQoL is generally poor, particularly for subjective constructs such as emotion and pain [68, 69].

Limitations include the different eligibility criteria in terms of the number of weeks of gestation or birth weight for different constituent study cohorts. Given differences in recruitment mechanisms of study participants, with some cohorts recruiting controls during childhood, it was not possible to examine HRQoL impacts by gestational week or birth weight at a more granular level. Furthermore, although our meta-analyses adjusted for maternal education, we acknowledge that we have not accounted for other socio-economic determinants of health. Finally, the results of this study might not be applicable to low-income or middle-income countries as the data used in this study were collected in high-income countries. Equally, our findings might not be fully applicable to the Americas, Asia or Africa as our study only included cohorts from Western European countries, Australia and New Zealand, limiting the external validity of the results presented.

## 4.2 Implications

The results indicate that the HUI3 MAU measure may be more sensitive at detecting differences in HRQoL following the long-term sequelae of preterm birth or low birthweight than the SF-36/12 and hence the SF-6D. Our results show that the HUI3 and SF-6D instruments might not be interchangeable for use in clinical and population research, and cost-effectiveness-based decision making that considers the long-term consequences of VP/VLBW status [70, 71]. The HUI3 might be preferred to the SF-6D in economic and policy evaluations that quantify particularly physical health or cognitive outcomes in individuals born VP/VLBW. Our results suggest that differences in the health descriptive systems of the HUI3 and SF-6D measures likely drive the differences in MAU scores of VP/VLBW individuals and controls in adulthood. Results presented in this study indicate that these two measures mostly do not seem to measure similar constructs, implying complementarity between the two HRQoL measures.

## 5 Conclusions

Results from five prospective longitudinal cohort studies previously identified by published systematic reviews [7, 30] demonstrate that VP/VLBW status is predominantly associated with decrements in physical and cognitive aspects of HRQoL during adulthood. Studies that estimate the effects of VP/VLBW status on multi-dimensional HRQoL outcomes in later adulthood are needed.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s40273-022-01201-2>.

## Declarations

**Authors' Contributions** Concept and design: CB, SVP, SVB, EV, SP. Acquisition of data: CB, SVP, SVB, EV, SP, DW, MM, NB, PJA, JLYC, LWD. Design, and implementation of the econometric data analysis: CB. Interpretation of data: CB, SP. Drafting of the manuscript: CB, SP. Critical revision of the paper for important intellectual content: CB, SVP, SVB, PJA, PB, NB, JLYC, BAD, LWD, KAIE, JH, MSI, SJ, NM, MM, YN, DW, LWD, EV, SP.

**Funding** This work was supported by grant 733280 from the European Commission as part of the Research on European Children and Adults Born Preterm (RECAP) Consortium Preterm Project, a European Union Horizon 2020 study to construct a platform combining data from cohort studies of very preterm birth in Europe. The Victorian Infant Collaborative Study was supported by grants 491246 and 546519 from the National Health and Medical Research Council of Australia. The New Zealand Very Low Birthweight Follow up Study was supported by project grant 12-129 from the Health Research Council of New Zealand and additional funding from the Cure Kids Charitable Foundation. Participation by the Norwegian University of Science and Technology in RECAP was supported by the Research Council of Norway, project no. 283791. SP receives support as a UK National Institute for Health Research Senior Investigator (NF-SI-0616-10103) and from the UK National Institute for Health Research Applied Research Collaboration Oxford and Thames Valley.

**Conflict of interest** The authors have no conflicts of interest to declare.

**Ethics Approval** Not applicable as this study describes secondary data analyses.

**Consent to Participate** Not applicable.

**Consent for Publication** Not applicable.

**Availability of Data and Material** Information regarding the data availability can be found at: <https://recap-preterm.eu/for-scientists/the-recap-preterm-cohort-platform/>.

**Code Availability** The code used in this study is available from the authors upon reasonable request.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative


Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

## References

- Hovi P, Vohr B, Ment LR, et al. Blood pressure in young adults born at very low birth weight: adults born preterm international collaboration. *Hypertension*. 2016;68:880–7.
- Parkinson JRC, Hyde MJ, Gale C, Santhakumaran S, Modi N. Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis. *Pediatrics*. 2013;131:e1240–63.
- Cooper R, Atherton K, Power C. Gestational age and risk factors for cardiovascular disease: evidence from the 1958 British birth cohort followed to mid-life. *Int J Epidemiol*. 2009;38:235–44.
- Doyle LW, Spittle A, Anderson PJ, Cheong JLY. School-aged neurodevelopmental outcomes for children born extremely preterm. *Arch Dis Child*. 2021;106(9):834–8.
- Pascal A, Govaert P, Oostra A, Naulaers G, Ortibus E, Broeck C. Neurodevelopmental outcome in very preterm and very-low-birthweight infants born over the past decade: a meta-analytic review. *Dev Med Child Neurol*. 2018;60:342–55.
- Serenius F, Källén K, Blennow M, et al. Neurodevelopmental outcome in extremely preterm infants at 2.5 years after active perinatal care in Sweden. *JAMA*. 2013;309:1810–20.
- Pal S, Steinhof M, Grevinga M, Wolke D, Verrips G. Quality of life of adults born very preterm or very low birth weight: a systematic review. *Acta Paediatr*. 2020;109:1974–88.
- Lund LK, Vik T, Lydersen S, et al. Mental health, quality of life and social relations in young adults born with low birth weight. *Health Qual Life Outcomes*. 2012;10:1–10.
- Allen MC, Cristofalo E, Kim C. Preterm birth: transition to adulthood. *Dev Disabil Res Rev*. 2010;16:323–35.
- Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. *N Engl J Med*. 2008;359:262–73.
- Beam AL, Fried I, Palmer N, et al. Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008–2016. *J Perinatol*. 2020;40:1091–9.
- Petrou S, Yiu HH, Kwon J. Economic consequences of preterm birth: a systematic review of the recent literature (2009–2017). *Arch Dis Child*. 2019;104:456–65.
- Horvath H, Brindis CD, Reyes EM, Yamey G, Franck L. Preterm birth: the role of knowledge transfer and exchange. *Health Res Policy Syst*. 2017;15:1–14.
- Treyvaud K, Lee KJ, Doyle LW, Anderson PJ. Very preterm birth influences parental mental health and family outcomes seven years after birth. *J Pediatr*. 2014;164:515–21.
- Misund AR, Nerdrum P, Diseth TH. Mental health in women experiencing preterm birth. *BMC Pregnancy Childbirth*. 2014;14:1–8.
- Petrou S. Economic consequences of preterm birth and low birthweight. *BJOG*. 2003;110:17–23.
- Petrou S, Sach T, Davidson L. The long-term costs of preterm birth and low birth weight: results of a systematic review. *Child Care Health Dev*. 2001;27:97–115.
- Barile JP, Reeve BB, Smith AW, et al. Monitoring population health for Healthy People 2020: evaluation of the NIH PROMIS R Global Health, CDC Healthy Days, and satisfaction with life instruments. *Qual Life Res*. 2013;22:1201–11.
- Moriarty DG, Zack MM, Kobau R. The Centers for Disease Control and Prevention's healthy days measures: population tracking of perceived physical and mental health over time. *Health Qual Life Outcomes*. 2003;1:1–8.
- Canadian Agency for Drug and Health Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada 2006.
- Chim L, Kelly PJ, Salkeld G, Stockler MR. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? *Pharmacoeconomics*. 2010;28:463–75.
- Excellence Care. Guide to the methods of technology appraisal 2013.
- Schron E, Friedmann E, Thomas SA. Does health-related quality of life predict hospitalization or mortality in patients with atrial fibrillation? *J Cardiovasc Electrophysiol*. 2014;25:23–8.
- Latham K, Peek CW. Self-rated health and morbidity onset among late midlife US adults. *J Gerontol B Psychol Sci Soc Sci*. 2013;68:107–16.
- DeSalvo KB, Jones TM, Peabody J, et al. Health care expenditure prediction with a single item, self-rated health measure. *Med Care*. 2009;47:440–7.
- Mouillet G, Falcoz A, Fritsch J, et al. Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice. *Qual Life Res*. 2021;30:3255–66.
- Nguyen MH, Huang FF, O'Neill SG. Patient-reported outcomes for quality of life in SLE: essential in clinical trials and ready for routine care. *J Clin Med*. 2021;10:3754.
- Chen TH, Li L, Michael MK, et al. A systematic review: how to choose appropriate health-related quality of life (HRQOL) measures in routine general practice? *J Zhejiang Univ Sci*. 2005;6:936–40.
- Pais-Ribeiro JL. Quality of life is a primary end-point in clinical settings. *Clin Nutr*. 2004;23:121–30.
- Petrou S, Krabuanrat N, Khan K. Preference-based health-related quality of life outcomes associated with preterm birth: a systematic review and meta-analysis. *Pharmacoeconomics*. 2020;38:357–73.
- Saigal S, Ferro MA, Van Lieshout RJ, Schmidt LA, Morrison KM, Boyle MH. Health-related quality of life trajectories of extremely low birth weight survivors into adulthood. *J Pediatr*. 2016;179:68–73.
- Baumann N, Bartmann P, Wolke D. Health-related quality of life into adulthood after very preterm birth. *Pediatrics*. 2016;137:e20153148.
- Roberts G, Burnett AC, Lee KJ, et al. Quality of life at age 18 years after extremely preterm birth in the post-surfactant era. *J Pediatr*. 2013;163:1008–13.
- Saigal S, Stoskopf B, Streiner D, Paneth N, Pinelli J, Boyle M. Growth trajectories of extremely low birth weight infants from birth to young adulthood: a longitudinal, population-based study. *Pediatr Res*. 2006;60:751–8.
- Batsvik B, Vederhus BJ, Halvorsen T, Wentzel-Larsen T, Graue M, Markestad T. Health-related quality of life may deteriorate from adolescence to young adulthood after extremely preterm birth. *Acta Paediatr*. 2015;104:948–55.
- Cooke RWI. Health, lifestyle, and quality of life for young adults born very preterm. *Arch Dis Child*. 2004;89:201–6.
- Poole KL, Islam UA, Schmidt LA, et al. Childhood motor function, health related quality of life and social functioning among emerging adults born at term or extremely low birth weight. *J Dev Phys Disabil*. 2017;29:369–83.
- Darlow BA, Horwood LJ, Pere-Bracken HM, Woodward LJ. Psychosocial outcomes of young adults born very low birth weight. *Pediatrics*. 2013;132:e1521–8.
- Sentenac M, Boutron I, Draper ES, et al. Defining very preterm populations for systematic reviews with meta-analyses. *JAMA Pediatr*. 2020;174:997–9.

40. Goldberg M, Chastang JF, Leclerc A, et al. Socioeconomic, demographic, occupational, and health factors associated with participation in a long-term epidemiologic survey: a prospective study of the French GAZEL cohort and its target population. *Am J Epidemiol.* 2001;154:373–84.
41. Wolke D, Waylen A, Samara M, et al. Selective drop-out in longitudinal studies and non-biased prediction of behaviour disorders. *Br J Psychiatry.* 2009;195:249–56.
42. Howe LD, Tilling K, Galobardes B, Lawlor DA. Loss to follow-up in cohort studies: bias in estimates of socioeconomic inequalities. *Epidemiology.* 2013;24:1–9.
43. Knudsen AK, Hotopf M, Skogen JC, Øverland S, Mykletun A. The health status of nonparticipants in a population-based health study: the Hordaland Health Study. *Am J Epidemiol.* 2010;172:1306–14.
44. Arnett JJ. *The Oxford handbook of emerging adulthood.* Oxford: Oxford University Press; 2015.
45. Lunenburg A, Pal SM, Dommelen P, et al. Changes in quality of life into adulthood after very preterm birth and/or very low birth weight in the Netherlands. *Health Qual Life Outcomes.* 2013;11:1–8.
46. Eryigit MS, Baumann N, Jaekel J, Bartmann P, Wolke D. Neurocognitive performance of very preterm or very low birth weight adults at 26 years. *J Child Psychol Psychiatry.* 2015;56:857–64.
47. Doyle LW, Cheong JLY, Burnett A, et al. Biological and social influences on outcomes of extreme-preterm/low-birth weight adolescents. *Pediatrics.* 2015;136:e1513–20.
48. Linsell L, Johnson S, Wolke D, et al. Cognitive trajectories from infancy to early adulthood following birth before 26 weeks of gestation: a prospective, population-based cohort study. *Arch Dis Child.* 2018;103:363–70.
49. Woodward LJ, Lu Z, Morris AR, Healey DM. Preschool self regulation predicts later mental health and educational achievement in very preterm and typically developing children. *Clin Neuropsychol.* 2017;31:404–22.
50. Evensen KAI, Aakvik KAD, Hollund IMH, Skranes J, Brubakk AM, Indredavik MS. Multidisciplinary and neuroimaging findings in preterm born very low birthweight individuals from birth to 28 years of age: a systematic review of a Norwegian prospective cohort study. *Paediatr Perinat Epidemiol.* 2022;36(5):606–30.
51. Darlow BA, Woodward LJ, Levin KJ, Melzer T, Horwood LJ. Perinatal and childhood predictors of general cognitive outcome at 28 years in a very-low-birthweight national cohort. *Dev Med Child Neurol.* 2020;62:1423–8.
52. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. *Ann Med.* 2001;33:375–84.
53. Furlong W, Feeny D, Torrance G, et al. Multiplicative multi-attribute utility function for the Health Utilities Index Mark 3 (HUI3) system: a technical report tech. rep. Hamilton (ON): Centre for Health Economics and Policy Analysis (CHEPA), McMaster University; 1998.
54. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. *Pharmacoeconomics.* 1995;7:490–502.
55. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. *Med Care.* 1996;34:702–22.
56. University of Sheffield. SF-6D: calculating QALYs from the SF-36 and SF-12. 2021.
57. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *J Health Econ.* 2002;21:271–92.
58. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res.* 2005;14:1523–32.
59. Brazier J, Ratcliffe J, Saloman J, Tsuchiya A. *Measuring and valuing health benefits for economic evaluation.* Oxford: Oxford University Press; 2017.
60. Statistics UNESCO Institute. International standard classification of education: ISCED 2011. *Comp Soc Res.* 2012;30:2.
61. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med.* 2017;36:855–75.
62. Richardson J, Khan MA, Iezzi A, Maxwell A. Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments. *Med Decis Making.* 2015;35:276–91.
63. Wolke D, Johnson S, Mendonça M. The life course consequences of very preterm birth. *Annu Rev Dev Psychol.* 2019;1:69–92.
64. Wolke D. Is social inequality in cognitive outcomes increased by preterm birth-related complications? *JAMA Netw Open.* 2019;2:e192902.
65. Eves R, Mendonça M, Baumann N, et al. Association of very preterm birth or very low birth weight with intelligence in adulthood: an individual participant data meta-analysis. *JAMA Pediatr.* 2021;175: e211058.
66. Cheong JLY, Haikerwal A, Anderson PJ, Doyle LW. Outcomes into adulthood of infants born extremely preterm. *Semin Perinatol.* 2021;45: 151483.
67. Anderson PJ, de Miranda DM, Albuquerque MR, et al. Psychiatric disorders in individuals born very preterm/very low-birth weight: an individual participant data (IPD) meta-analysis. *EclinicalMedicine.* 2021;42: 101216.
68. Wolke D. Born extremely low birth weight and health related quality of life into adulthood. *J Pediatr.* 2016;179:11–2.
69. Verrips GHW, Stuifbergen MC, Den Ouden AL, et al. Measuring health status using the Health Utilities Index: agreement between raters and between modalities of administration. *J Clin Epidemiol.* 2001;54:475–81.
70. Frey HA, Klebanoff MA. The epidemiology, etiology, and costs of preterm birth. *Semin Fetal Neonatal Med.* 2016;21:68–73.
71. Johnston KM, Gooch K, Korol E, et al. The economic burden of prematurity in Canada. *BMC Pediatr.* 2014;14:1–10.

## Authors and Affiliations

Corneliu Bolbocean<sup>1</sup>  · Sylvia van der Pal<sup>2</sup> · Stef van Buuren<sup>2</sup> · Peter J. Anderson<sup>3,4</sup> · Peter Bartmann<sup>5</sup> · Nicole Baumann<sup>3,6,7</sup> · Jeanie L. Y. Cheong<sup>8</sup> · Brian A. Darlow<sup>9</sup> · Lex W. Doyle<sup>8,10</sup> · Kari Anne I. Evensen<sup>11,12</sup> · John Horwood<sup>13</sup> · Marit S. Indredavik<sup>14</sup> · Samantha Johnson<sup>6</sup> · Neil Marlow<sup>15</sup> · Marina Mendonça<sup>8</sup> · Yanyan Ni<sup>8,15</sup> · Dieter Wolke<sup>16</sup> · Lianne Woodward<sup>17</sup> · Erik Verrips<sup>2</sup> · Stavros Petrou<sup>1</sup>

<sup>1</sup> Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK

<sup>2</sup> Netherlands Organisation for Applied Scientific Research, The Hague, the Netherlands

<sup>3</sup> Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, VIC, Australia

<sup>4</sup> Clinical Sciences, Murdoch Children's Research Institute, Melbourne, VIC, Australia

<sup>5</sup> Department of Neonatology and Paediatric Intensive Care, University Hospital Bonn, Children's Hospital, Bonn, Germany

<sup>6</sup> Department of Health Sciences, University of Leicester, Leicester, UK

<sup>7</sup> Department of Psychology, University of Warwick, Warwick, UK

<sup>8</sup> Department of Obstetrics and Gynaecology, Clinical Sciences, Murdoch Children's Research Institute, Newborn Services, Royal Women's Hospital, University of Melbourne, Melbourne, VIC, Australia

<sup>9</sup> Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand

<sup>10</sup> Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia

<sup>11</sup> Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

<sup>12</sup> Department of Rehabilitation Science and Health Technology, Oslo Metropolitan University, Oslo, Norway

<sup>13</sup> Department of Psychological Medicine, University of Otago Christchurch, Christchurch, New Zealand

<sup>14</sup> Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

<sup>15</sup> UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK

<sup>16</sup> Department of Psychology, Warwick Medical School, University of Warwick and Division of Health Sciences, Warwick, UK

<sup>17</sup> Faculty of Health, University of Canterbury, Christchurch, New Zealand